{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679754401152.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.5649/jjphcs.41.603"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/jjphcs/41/9/41_603/_pdf"}},{"identifier":{"@type":"NAID","@value":"130006855779"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2016154553"}}],"dc:title":[{"@language":"ja","@value":"乳がん術前・術後化学療法としてのアントラサイクリン／シクロホスファミド併用療法に対する予防的制吐療法におけるアプレピタントおよびデキサメタゾンの有効性および安全性"},{"@language":"en","@value":"Efficacy and Safety of Aprepitant and Dexamethasone in the Prevention of Nausea and Vomiting from Neoadjuvant or Adjuvant Anthracyclines and Cyclophosphamide Combination Therapy in Patients with Breast Cancer"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<p>Here we report the efficacy of the prophylactic antiemetic therapy that is recommended as high emetic risk by the American Society of Clinical Oncology (ASCO) guideline (2011) for anthracyclines and cyclophosphamide combination therapy (AC, CEF therapy) as neoadjuvant or adjuvant chemotherapy in breast cancer. In the National Cancer Center Hospital, aprepitant (APR) has been used in AC, CEF therapy since 2010, and additional day 2-4 dosages of dexamethasone (DEX) since 2012, following the ASCO guidelines (2006 / 2011). However, neither the efficacy nor the details of DEX dosage given concomitantly with APR in AC, CEF therapy have been fully established. We retrospectively investigated the incidence of nausea and vomiting before and after the introduction of APR therapy with or without additional use of DEX in breast cancer patients treated with preoperative or postoperative AC, CEF therapy in the hospital to confirm the efficacy and safety of the prophylactic antiemetic therapy. In 338 patients who received the treatment between January 2009 and December 2010, the incidence of vomiting decreased in the APR administered group (<i>P</i> = 0.020), while the degree of nausea increased (<i>P</i> = 0.003). In addition, in 369 patients who received the treatment between May 2011 and May 2013, the degree of nausea was significantly improved by APR with additional day 2-4 DEX dosages (<i>P</i> < 0.001). No adverse events associated with the additional dosage of DEX were observed. These results seem to positively support the efficacy of antiemetic prophylaxis recommended by the ASCO guideline (2011).</p>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282679754401154","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588575"}],"foaf:name":[{"@language":"ja","@value":"原 茉梨絵"},{"@language":"en","@value":"Hara Marie"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401292","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588583"}],"foaf:name":[{"@language":"ja","@value":"中島 寿久"},{"@language":"en","@value":"Nakashima Toshihisa"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401287","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588585"}],"foaf:name":[{"@language":"ja","@value":"龍島 靖明"},{"@language":"en","@value":"Ryushima Yasuaki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401152","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588586"}],"foaf:name":[{"@language":"ja","@value":"清水 千佳子"},{"@language":"en","@value":"Shimizu Chikako"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401288","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588587"}],"foaf:name":[{"@language":"ja","@value":"公平 誠"},{"@language":"en","@value":"Kodaira Makoto"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401280","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588584"}],"foaf:name":[{"@language":"ja","@value":"原島 寿江"},{"@language":"en","@value":"Harashima Hisae"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401153","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588588"}],"foaf:name":[{"@language":"ja","@value":"温泉川 真由"},{"@language":"en","@value":"Yunokawa Mayu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401283","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588589"}],"foaf:name":[{"@language":"ja","@value":"山本 春風"},{"@language":"en","@value":"Yamamoto Harukaze"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401281","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588590"}],"foaf:name":[{"@language":"ja","@value":"橋本 淳"},{"@language":"en","@value":"Hashimoto Jun"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401286","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588576"}],"foaf:name":[{"@language":"ja","@value":"田辺 裕子"},{"@language":"en","@value":"Tanabe Yuko"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401290","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588577"}],"foaf:name":[{"@language":"ja","@value":"文 靖子"},{"@language":"en","@value":"Bun Seiko"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401289","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588578"}],"foaf:name":[{"@language":"ja","@value":"牧野 好倫"},{"@language":"en","@value":"Makino Yoshinori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401285","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588579"}],"foaf:name":[{"@language":"ja","@value":"岩瀬 治雄"},{"@language":"en","@value":"Iwase Haruo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401284","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588580"}],"foaf:name":[{"@language":"ja","@value":"藤原 康弘"},{"@language":"en","@value":"Fujiwara Yasuhiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401282","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588582"}],"foaf:name":[{"@language":"ja","@value":"林 憲一"},{"@language":"en","@value":"Hayashi Yoshikazu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 薬剤部"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679754401291","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000391588581"}],"foaf:name":[{"@language":"ja","@value":"田村 研治"},{"@language":"en","@value":"Tamura Kenji"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Medical Oncology, National Cancer Center Hospital"},{"@language":"ja","@value":"国立がん研究センター中央病院 乳腺・腫瘍内科"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"1346342X"},{"@type":"LISSN","@value":"1346342X"},{"@type":"EISSN","@value":"18821499"}],"prism:publicationName":[{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"ja","@value":"医療薬学"},{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"en","@value":"JJPHCS"},{"@language":"en","@value":"Jpn. J. Pharm. Health Care Sci."},{"@language":"ja","@value":"医療薬学"}],"dc:publisher":[{"@language":"en","@value":"Japanese Society of Pharmaceutical Health Care and Sciences"},{"@language":"ja","@value":"一般社団法人日本医療薬学会"}],"prism:publicationDate":"2015","prism:volume":"41","prism:number":"9","prism:startingPage":"603","prism:endingPage":"611"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://www.jstage.jst.go.jp/article/jjphcs/41/9/41_603/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2016154553"}],"availableAt":"2015","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=aprepitant","dc:title":"aprepitant"},{"@id":"https://cir.nii.ac.jp/all?q=dexamethasone","dc:title":"dexamethasone"},{"@id":"https://cir.nii.ac.jp/all?q=nausea","dc:title":"nausea"},{"@id":"https://cir.nii.ac.jp/all?q=vomiting","dc:title":"vomiting"},{"@id":"https://cir.nii.ac.jp/all?q=chemotherapy","dc:title":"chemotherapy"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1361137044752401408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Establishing the dose of the oral NK<sub>1</sub> antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518378853504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized, Double-Blind, Dose-Finding Study of Dexamethasone in Preventing Acute Emesis Induced by Anthracyclines, Carboplatin, or Cyclophosphamide:"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518445133184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994937972224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"MECHANISM OF DECLINE IN RAT BRAIN 5‐HYDROXYTRYPTAMINE AFTER INDUCTION OF LIVER TRYPTOPHAN PYRROLASE BY HYDROCORTISONE: ROLES OF TRYPTOPHAN CATABOLISM AND KYNURENINE SYNTHESIS"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469077137920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469401751424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471087631744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943560424704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944754180352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944891362176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Methodology of antiemetic trials: A review"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419265015168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320223455488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320299767552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793407891328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268425289856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269616303872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270974408320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204775700992","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"ドキソルビシン／シクロホスファミド併用療法施行乳がん患者における化学療法誘発性悪心・嘔吐に対するアプレピタントの効果の検討"},{"@language":"en","@value":"Comparative Investigation of the Antiemetic Efficacy of Aprepitant Containing Antiemetic Regimen in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Combination Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681103562624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"シスプラチンによる遅発性悪心•嘔吐に対する薬物療法の検討：システマティック•レビュー"},{"@language":"en","@value":"Effectiveness of Anti-emetics for the Prophylaxis of Cisplatin-Induced Delayed Emesis : A Systematic Review"},{"@value":"シスプラチンによる遅発性悪心・嘔吐に対する薬物療法の検討:システマティック・レビュー"},{"@language":"ja-Kana","@value":"シスプラチン ニ ヨル チハツ セイオシン オウト ニ タイスル ヤクブツ リョウホウ ノ ケントウ システマティック レビュー"}]},{"@id":"https://cir.nii.ac.jp/crid/1390286426515302912","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Relationship between PONV and S-1 Adjuvant Chemotherapy-associated Nausea"},{"@language":"ja","@value":"S-1術後補助化学療法における悪心発現と術後悪心・嘔吐歴との関連性"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2001197045"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.41.603"},{"@type":"CIA","@value":"130006855779"},{"@type":"OPENAIRE","@value":"doi_dedup___::cae6e629884b0a6e4f4fec6c88aafa7d"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.45.626_references_DOI_IX0XkcAHRhCZHNBuhrGqbt7ZAA3"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.43.1_references_DOI_IX0XkcAHRhCZHNBuhrGqbt7ZAA3"}]}